N/A:NEUE
NeueHealth, Inc.
NeueHealth delivers clinically validated digital therapeutics platforms that treat chronic diseases and behavioral health conditions through scalable software solutions.
Key Metrics
Investment Thesis
Bull Case
Despite current financial distress, NeueHealth holds a unique position in the growing digital therapeutics market with FDA-cleared products that address high-need chronic conditions like diabetes and depression. If the company can successfully optimize its cost structure or secure strategic partnerships to stabilize cash flow, its established clinical IP could become highly valuable as payers increasingly seek non-pharmacological interventions. The potential for regulatory expansion into new therapeutic areas could unlock significant growth if the company survives its current liquidity crunch.
Bear Case
The stock presents a high-risk profile given the persistent negative net income, massive debt burden, and alarming revenue decline over the past three years that suggests fundamental business model issues. With cash reserves of only $83.3M against total liabilities of $930.5M, the company faces an imminent threat of insolvency or forced asset sales unless it achieves rapid profitability improvements. Investors should avoid this stock until there is clear evidence of a turnaround strategy that addresses the severe operating losses and shrinking market share.
About NeueHealth, Inc.
NeueHealth Inc. is a leading global provider of digital therapeutics and behavioral health solutions, serving patients, healthcare providers, and payers across the United States and international markets. The company leverages proprietary clinical algorithms to deliver evidence-based software interventions for chronic conditions like diabetes, hypertension, and mental health disorders. Its revenue model combines direct sales with partnerships to scale access to clinically validated digital care programs.
Analysis
Management Discussion
Recent financial performance reflects a severe contraction in both revenue and profitability, with 2024 revenue declining to $936.7M from $1.16B in 2023 and net income remaining deeply negative at -$99.7M. The company has utilized significant debt issuance of $119.8M and experienced a massive cash outflow from financing activities of -$253.6M, likely to fund ongoing operations amidst declining top-line growth. Despite these challenges, the firm continues to invest in intangible assets and maintain a substantial accounts receivable balance of $36.6M, suggesting active customer engagement even as profitability remains elusive.
Industry Overview
The digital therapeutics industry is experiencing rapid expansion as healthcare systems seek cost-effective, scalable solutions for managing chronic diseases and mental health disorders. Regulatory bodies like the FDA are increasingly providing pathways for software-based interventions, which validates the market potential but also raises the barrier to entry through rigorous clinical evidence requirements. Competition is intensifying from both traditional pharmaceutical companies entering the DTx space and specialized startups, pressuring margins and requiring continuous innovation to maintain relevance.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $2.41B | $1.16B | $936.7M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $2.41B | $1.16B | $936.7M |
| Operating Expenses | $3.03B | $1.74B | $1.04B |
| Operating Income | $-622.2M | $-577.0M | $-107.4M |
| G&A | $77.0M | $26.5M | — |
| Marketing | $82.3M | — | — |
| Stock-Based Comp | $109.7M | $83.7M | $70.2M |
| D&A | $50.4M | $24.2M | $15.6M |
| Depreciation | $12.2M | $6.6M | $4.9M |
| Amortization | $38.2M | $11.7M | $10.8M |
| Other OpEx | $2.87B | $1.71B | — |
| Non-Operating Income | $-12.0M | $-52.2M | $7.9M |
| Interest Expense | $12.8M | $38.2M | — |
| Pre-Tax Income | $-634.3M | $-629.2M | $-99.5M |
| Income Tax | $3.7M | $-1.4M | $2.6M |
| Continuing Ops | $-773.3M | $-562.5M | $-188.7M |
| Discontinued Ops | $-721.9M | $-638.1M | $2.3M |
| Net Income | $-1.36B | $-1.27B | $-99.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-1.36B | $-1.27B | $-99.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $3.57B | $1.09B | $434.6M |
| Cash & Equivalents | $466.3M | $87.3M | $83.3M |
| Marketable Securities | $13.2M | $6.3M | $9.9M |
| Accounts Receivable | $73.6M | $39.1M | $36.6M |
| Prepaid Expenses | $134.8M | $17.8M | $36.8M |
| Other Current Assets | $2.88B | $938.4M | $268.1M |
| Long-Term Assets | $1.09B | $136.6M | $109.7M |
| PP&E (Net) | $42.6M | $14.5M | $11.2M |
| Intangibles | $249.1M | $93.2M | $71.1M |
| Goodwill | $760.1M | $0 | — |
| Operating Leases | — | $26.8M | $22.3M |
| LT Investments | $5.4M | $0 | — |
| Other LT Assets | $37.3M | $2.1M | $5.1M |
| Total Assets | $4.67B | $1.23B | $544.4M |
| Current Liabilities | $3.69B | $1.39B | $710.2M |
| Accounts Payable | $67.9M | $11.8M | $6.3M |
| Current Debt | — | — | $2.0M |
| Current Leases | $12.7M | $7.1M | $6.3M |
| Other Current Liab | $3.61B | $1.37B | $695.6M |
| Long-Term Liabilities | $36.7M | $88.8M | $220.3M |
| Long-Term Debt | — | — | $202.6M |
| LT Operating Leases | $33.5M | $22.4M | $17.6M |
| Other LT Liab | $3.2M | $66.4M | $66.0K |
| Total Liabilities | $3.73B | $1.48B | $930.5M |
| Shareholders' Equity | $939.7M | $-254.6M | $-386.1M |
| Paid-In Capital | $2.97B | $3.06B | $3.10B |
| Retained Earnings | $-3.16B | $-4.31B | $-4.44B |
| AOCI | $-4.4M | $-122.0K | $0 |
| Total L&E | $4.67B | $1.23B | $544.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-1.36B | $-1.27B | $-99.7M |
| Non-Cash Adjustments | $1.36B | $-481.5M | $23.5M |
| Working Capital Changes | $232.5M | $-979.2M | $-47.0M |
| Cash from Operations | $234.5M | $-2.73B | $-123.2M |
| Capital Expenditures | $27.4M | $2.9M | $2.3M |
| Cash from Investing | $-429.7M | $1.12B | $186.9M |
| Debt Issuances | — | $66.4M | $119.8M |
| Cash from Financing | $1.07B | $49.9M | $-253.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $871.1M | $-1.56B | $-189.9M |
| Beginning Cash | $1.06B | $1.93B | $375.3M |
| Ending Cash | $1.93B | $375.3M | $185.4M |
Frequently Asked Questions
How does NeueHealth, Inc. make money?
The company operates primarily through its Digital Therapeutics (DTx) platform, which includes proprietary clinical algorithms for managing conditions such as type 2 diabetes, hypertension, heart failure, depression, and anxiety. Revenue streams also derive from licensing these digital interventions to healthcare systems, payers, and employers, as well as providing managed care services that integrate DTx into existing patient workflows.
What are the main risks for NEUE?
The company faces significant cash burn risks with operating cash flow of -$123.2M and a substantial retained earnings deficit of -$4.44B, raising concerns about liquidity sustainability without further financing. Revenue contraction trends are evident with revenue dropping from $2.41B in 2022 to $936.7M in 2024, indicating potential market saturation or competitive displacement that could further erode financial stability. High current liabilities of $710.2M against only $83.3M in cash and equivalents creates immediate solvency pressure, especially given the negative net profit trend over the last three years.
What is NEUE's competitive advantage?
NeueHealth possesses a robust intellectual property portfolio with FDA-cleared or cleared-by-FDA digital therapeutics that provide clinically proven outcomes without requiring new drugs or invasive procedures. The company benefits from strong payer and provider reimbursement networks, allowing its solutions to be covered by insurance plans, which accelerates patient adoption and scalability. Its proprietary clinical algorithms are continuously refined through real-world data, creating a compounding asset that improves efficacy over time.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.